You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGentamicin
Accession NumberDB00798  (APRD00214)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1a, obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (genetic translation).
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alcomicin Oph Sol 3mg/mlLiquid3 mgOphthalmicAlcon Canada Inc1983-12-312009-04-24Canada
Cidomycin Inj 10mg/mlLiquid10 mgIntramuscular; IntravenousHoechst Roussel Canada Inc.1995-12-312000-07-28Canada
Cidomycin Inj 40mg/mlLiquid40 mgIntramuscular; IntravenousHoechst Roussel Canada Inc.1995-12-311999-08-20Canada
Cidomycin Inj 40mg/mlLiquid40 mgIntramuscular; IntravenousRoussel Canada Inc.1979-12-311997-08-05Canada
Cidomycin Inj Pediatric 10mgLiquid10 mgIntramuscular; IntravenousRoussel Canada Inc.1972-12-311997-08-05Canada
Diogent Ointment 0.3%Ointment.3 %OphthalmicDioptic Pharmaceuticals Inc1994-12-31Not applicableCanada
Diogent Solution 0.3%Liquid.3 %OphthalmicDioptic Pharmaceuticals Inc1994-12-31Not applicableCanada
Garamycin Cream 0.1%Cream.1 %TopicalSchering Plough Canada Inc1966-12-312007-08-03Canada
Garamycin Inj 10mg/ml PediatricSolution10 mgIntramuscular; IntravenousSchering Plough Canada Inc1970-12-312004-07-21Canada
Garamycin Inj 40mg/mlSolution40 mgIntramuscular; IntravenousSchering Plough Canada Inc1966-12-312004-07-21Canada
Garamycin Ont 0.1%Ointment1 mgTopicalSchering Plough Canada Inc1966-12-312007-08-03Canada
Garamycin Ophthalmic Drops 0.3%Solution / drops3 mgOphthalmicMerck Canada Inc1981-12-312014-09-02Canada
Garamycin Ophthalmic Ointment 0.3%Ointment0.3 %OphthalmicMerck Canada Inc1969-12-312013-07-15Canada
Garamycin Otic Drops 0.3%Solution / drops3 mgAuricular (otic)Merck Canada Inc1981-12-312014-03-03Canada
Garatec Ophthalmic Dps 5mg/mlSolution / drops5 mgOphthalmicTechnilab Pharma Inc.1992-12-312004-08-03Canada
Garatec Otic Dps 5mg/mlSolution / drops5 mgAuricular (otic)Technilab Pharma Inc.1992-12-312004-08-03Canada
Gentacidin Oph Soln 3mg/mlSolution / drops3 mgOphthalmicIolab Pharmaceuticals1991-12-311996-09-09Canada
Gentacidin Ophthalmic Solution 3mg/mlSolution / drops3 mgOphthalmicCiba Vision Canada Inc1996-12-312000-06-30Canada
GentamicinSolution.3 %OphthalmicIvax Pharmaceuticals Incorporated1996-09-102015-10-26Canada
Gentamicin Injection USPSolution10 mgIntramuscular; IntravenousSandoz Canada Incorporated2005-08-29Not applicableCanada
Gentamicin Injection USPSolution40 mgIntramuscular; IntravenousTeligent OuNot applicableNot applicableCanada
Gentamicin Injection USPSolution40 mgIntramuscular; IntravenousSandoz Canada Incorporated2000-12-20Not applicableCanada
Gentamicin Sulphate 0.3% - Liq OphLiquid3 mgOphthalmicRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Gentamicin Sulphate Injection USP-10mg/mlSolution10 mgIntramuscular; IntravenousNovopharm Limited1995-12-312005-08-10Canada
Gentamicin Sulphate Injection USP-40mg/mlSolution40 mgIntramuscular; IntravenousNovopharm Limited1995-12-312005-08-10Canada
Gentamicin(e) 100mg Liq IV 1mg/mlSolution1 mgIntravenousBaxter Corporation1995-12-31Not applicableCanada
Gentamicin(e) 120mg Liq IV 1.2mg/mlSolution1.2 mgIntravenousBaxter Corporation1995-12-312016-07-15Canada
Gentamicin(e) 80mg Liq IV 1.6mg/mlSolution1.6 mgIntravenousBaxter Corporation1995-12-31Not applicableCanada
Gentrasul Liq 3mg/mlSolution / drops3 mgOphthalmicBausch & Lomb Canada Inc.1988-12-311996-09-09Canada
Gentrasul Oph Ointment 3mg/gmOintment3 mgOphthalmicBausch & Lomb Canada Inc.1988-12-311996-09-09Canada
Minims Gentamicin Sulfate 0.3%Solution / drops0.3 %Ophthalmic; TopicalChauvin Pharmaceuticals Limited1995-12-312009-02-04Canada
Ocugram Liq 3mg/mlLiquid3 mgOphthalmic; TopicalHerdt Et Charton Inc.1994-12-311999-01-16Canada
Ocugram Ont 3mg/gmOintment3 mgOphthalmic; TopicalHerdt Et Charton Inc.1994-12-311999-01-16Canada
Odan-gentamicinSolution5 mgOphthalmicOdan Laboratories Ltd1991-12-31Not applicableCanada
Odan-gentamicinOintment5 mgOphthalmicOdan Laboratories Ltd1994-12-31Not applicableCanada
PMS-gentamicin Cream 1mg/gmCream1 mgTopicalPharmascience Inc1990-12-31Not applicableCanada
PMS-gentamicin Ointment 1mg/gmOintment1 mgTopicalPharmascience Inc1990-12-31Not applicableCanada
PMS-gentamicin Ophthalmic Ointment 0.3%Ointment0.3 %OphthalmicPharmascience IncNot applicableNot applicableCanada
PMS-gentamicin Otic Drops 0.3%Solution / drops3 mgAuricular (otic)Pharmascience Inc1997-07-18Not applicableCanada
PMS-gentamicin Sulfate Oph Dps 0.3%Liquid3 mgOphthalmicPharmascience Inc1989-12-31Not applicableCanada
R.O.-gentycinLiquid3 mgOphthalmicRichmond Pharmaceuticals Inc.1992-12-311997-08-11Canada
Ratio-gentamicinOintment.1 %TopicalRatiopharm Inc Division Of Teva Canada Limited1990-12-312016-07-06Canada
Ratio-gentamicinCream0.1 %TopicalRatiopharm Inc Division Of Teva Canada Limited1990-12-312016-07-06Canada
Sandoz GentamicinSolution3 mgAuricular (otic)Sandoz Canada Incorporated1996-11-26Not applicableCanada
Sandoz GentamicinOintment3 mgOphthalmicSandoz Canada Incorporated1997-11-25Not applicableCanada
Sandoz GentamicinLiquid3 mgOphthalmicSandoz Canada Incorporated1997-05-06Not applicableCanada
SeptopalImplant4.5 mgParenteralBiomet Orthopedics, Inc.1987-10-192014-07-24Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GaramycinSolution / drops3 mg/mLOphthalmicFera Pharmaceuticals, LLC2011-05-152016-11-16Us
GaramycinOintment3 mg/gOphthalmicFera Pharmaceuticals, LLC2010-10-082016-11-18Us
Garamycin Gentamicin SulfateSolution3 mg/mLOphthalmicPaddock Laboratories, LLC2014-06-05Not applicableUs
GentakOintment3 mg/gOphthalmicA S Medication Solutions2006-05-08Not applicableUs
GentakOintment3 mg/gOphthalmicA S Medication Solutions Llc2006-05-08Not applicableUs
GentakOintment3 mg/gOphthalmicAkorn, Inc.2013-03-11Not applicableUs
GentakOintment3 mg/gOphthalmicREMEDYREPACK INC.2013-06-24Not applicableUs
GentakOintment3 mg/gOphthalmicAkorn, Inc.2006-05-08Not applicableUs
GentakOintment3 mg/gOphthalmicPreferred Pharmaceuticals, Inc.2012-10-23Not applicableUs
GentakOintment3 mg/gOphthalmicLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-27Not applicableUs
GentamicinInjection, solution10 mg/mLIntramuscular; IntravenousCardinal Health1982-03-04Not applicableUs
GentamicinInjection, solution10 mg/mLIntramuscular; IntravenousFresenius Kabi USA, LLC2004-11-29Not applicableUs
GentamicinInjection, solution10 mg/mLIntramuscular; IntravenousFresenius Kabi USA, LLC1982-03-04Not applicableUs
GentamicinInjection, solution40 mg/mLIntramuscular; IntravenousCardinal Health2000-08-10Not applicableUs
GentamicinInjection, solution40 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
GentamicinInjection, solution40 mg/mLIntramuscular; IntravenousFresenius Kabi USA, LLC2000-08-10Not applicableUs
GentamicinInjection, solution10 mg/mLIntramuscular; IntravenousCardinal Health2004-11-29Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicPreferred Pharmaceuticals, Inc.2014-03-25Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicLake Erie Medical & Surgical Suppy DBA Quality Care Products LLC1998-01-05Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicA S Medication Solutions2006-12-13Not applicableUs
Gentamicin SulfateCream1 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1984-07-05Not applicableUs
Gentamicin SulfateCream1 mg/gTopicalSTAT Rx USA LLC2009-08-11Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicBausch & Lomb Incorporated1994-05-11Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicUnit Dose Services1994-05-11Not applicableUs
Gentamicin SulfateSolution3 mg/mLOphthalmicA S Medication Solutions1996-04-05Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicPhysicians Total Care, Inc.1993-09-17Not applicableUs
Gentamicin SulfateInjection, solution, concentrate40 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicProficient Rx LP1994-05-11Not applicableUs
Gentamicin SulfateInjection, solution, concentrate10 mg/mLIntravenousHospira, Inc.2011-11-30Not applicableUs
Gentamicin SulfateOintment3 mg/gOphthalmicPhysicians Total Care, Inc.1994-09-21Not applicableUs
Gentamicin SulfateCream1 mg/gTopicalPerrigo New York Inc2006-08-23Not applicableUs
Gentamicin SulfateOintment1 mg/gTopicalPerrigo New York Inc2006-07-10Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicA S Medication Solutions1994-05-11Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicPacific Pharma, Inc.1998-01-05Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicA S Medication Solutions1998-01-05Not applicableUs
Gentamicin SulfateOintment1 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2010-03-17Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicAkorn, Inc.2006-12-13Not applicableUs
Gentamicin SulfateInjection, solution, concentrate40 mg/mLIntramuscular; IntravenousCardinal Health1983-08-15Not applicableUs
Gentamicin SulfateOintment3 mg/gOphthalmicFera Pharmaceuticals, LLC2011-01-032016-11-16Us
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicDIRECT RX2014-01-01Not applicableUs
Gentamicin SulfateCream1 mg/gTopicalDispensing Solutions, Inc.1984-07-05Not applicableUs
Gentamicin SulfateInjection, solution, concentrate10 mg/mLIntravenousHospira, Inc.2011-11-30Not applicableUs
Gentamicin SulfateSolution3 mg/mLOphthalmicRebel Distributors Corp1984-10-10Not applicableUs
Gentamicin SulfateOintment1 mg/gTopicalA S Medication Solutions Llc2010-03-17Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicPreferred Pharmaceuticals, Inc.2013-03-14Not applicableUs
Gentamicin SulfateCream1 mg/gTopicalPhysicians Total Care, Inc.1995-05-12Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicUnit Dose Services1994-05-11Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicMedsource Pharmaceuticals1994-05-11Not applicableUs
Gentamicin SulfateOintment3 mg/gOphthalmicA S Medication Solutions2013-12-12Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicREMEDYREPACK INC.2013-07-05Not applicableUs
Gentamicin SulfateSolution3 mg/mLOphthalmicSandoz Inc1996-04-05Not applicableUs
Gentamicin SulfateInjection, solution40 mg/mLIntramuscular; IntravenousHospira, Inc.1983-08-08Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicClinical Solutions Wholesale1994-05-11Not applicableUs
Gentamicin SulfateOintment3 mg/gOphthalmicPaddock Laboratories, LLC2013-12-12Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-12Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicREMEDYREPACK INC.2016-11-10Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicAidarex Pharmaceuticals LLC1998-01-05Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicA S Medication Solutions1994-05-11Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicA S Medication Solutions Llc1994-05-11Not applicableUs
Gentamicin SulfateOintment1 mg/gTopicalPhysicians Total Care, Inc.2010-06-02Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicPreferred Pharamcaeuticals Inc.2016-10-13Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicProficient Rx LP1998-01-05Not applicableUs
Gentamicin SulfateInjection, solution, concentrate10 mg/mLIntravenousHospira, Inc.2011-11-30Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicAkorn, Inc.2013-03-11Not applicableUs
Gentamicin SulfateOintment3 mg/gOphthalmicMwi2015-03-23Not applicableUs
Gentamicin SulfateSolution / drops3 mg/mLOphthalmicProficient Rx LP2006-12-13Not applicableUs
Gentamicin Sulfate In Sodium ChlorideInjection, solution1.4 mg/mLIntravenousHospira, Inc.2009-12-04Not applicableUs
Gentamicin Sulfate In Sodium ChlorideInjection, solution100 mg/100mLIntravenousBaxter Healthcare Corporation1982-09-07Not applicableUs
Gentamicin Sulfate In Sodium ChlorideInjection, solution1 mg/mLIntravenousHospira, Inc.2009-12-04Not applicableUs
Gentamicin Sulfate In Sodium ChlorideInjection, solution1.6 mg/mLIntravenousHospira, Inc.2009-12-04Not applicableUs
Gentamicin Sulfate In Sodium ChlorideInjection, solution60 mg/50mLIntravenousBaxter Healthcare Corporation1982-09-07Not applicableUs
Gentamicin Sulfate In Sodium ChlorideInjection, solution.8 mg/mLIntravenousHospira, Inc.2009-12-04Not applicableUs
Gentamicin Sulfate In Sodium ChlorideInjection, solution80 mg/50mLIntravenousBaxter Healthcare Corporation1982-09-07Not applicableUs
Gentamicin Sulfate In Sodium ChlorideInjection, solution1.2 mg/mLIntravenousHospira, Inc.2009-12-04Not applicableUs
Gentamicin Sulfate In Sodium ChlorideInjection, solution80 mg/100mLIntravenousBaxter Healthcare Corporation1982-09-07Not applicableUs
Gentamicin Sulfate In Sodium ChlorideInjection, solution.9 mg/mLIntravenousHospira, Inc.2009-12-04Not applicableUs
Gentamicin Sulfate In Sodium ChlorideInjection, solution100 mg/50mLIntravenousBaxter Healthcare Corporation1982-09-07Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlcomicinNot Available
BristagenNot Available
G-MycinNot Available
GenopticAllergan
GentacidinNot Available
GentafairNot Available
GentamarNot Available
JenamicinNot Available
Ocu-MycinNot Available
Spectro-GentaNot Available
U-gencinU-Liang
Brand mixtures
NameLabellerIngredients
Betamycin Ophthalmic/otic SolutionSterimax Inc
Diprogen OintmentMerck Canada Inc
Dom-gentamicin-betamethasoneDominion Pharmacal
Garasone Ophthalmic and Otic SolutionMerck Canada Inc
Garasone Ophthalmic OintmentMerck Canada Inc
Gentamicin Sulfate In 0.9% Sodium Chloride InjectionHospira Healthcare Corporation
Gentamicin Sulfate In Nacl 0.9% InjHospira Healthcare Corporation
Gentamicin Sulfate In Nacl O.9% InjHospira Healthcare Corporation
PMS-gentamicin-betamethasonePharmascience Inc
Pred-GAllergan, Inc.
Sandoz PentasoneSandoz Canada Incorporated
Valisone-G CreamValeant Canada Lp/valeant Canada s.e.c.
Valisone-G OintmentValeant Canada Lp Valeant Canada S.E.C.
Salts
Name/CASStructureProperties
Gentamicin sulfate
1405-41-0
ThumbNot applicableDBSALT000690
Categories
UNIIT6Z9V48IKG
CAS number1403-66-3
WeightAverage: 477.5954
Monoisotopic: 477.316248755
Chemical FormulaC21H43N5O7
InChI KeyCEAZRRDELHUEMR-UHFFFAOYSA-N
InChI
InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3
IUPAC Name
2-{[4,6-diamino-3-({3-amino-6-[1-(methylamino)ethyl]oxan-2-yl}oxy)-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol
SMILES
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1
Pharmacology
IndicationFor treatment of serious infections caused by susceptible strains of the following microorganisms: P. aeruginosa, Proteus species (indole-positive and indole-negative), E. coli, Klebsiella-Enterobactor-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative).
Structured Indications
PharmacodynamicsGentamicin is a broad spectrum aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.
Mechanism of actionAminoglycosides like gentamicin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically gentamicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.
TargetKindPharmacological actionActionsOrganismUniProt ID
30S ribosomal protein S12Proteinyes
adduct
Escherichia coli (strain K12)P0A7S3 details
16S rRNANucleotideyes
adduct
Enteric bacteria and other eubacterianot applicabledetails
Low-density lipoprotein receptor-related protein 2Proteinno
other/unknown
HumanP98164 details
NH(3)-dependent NAD(+) synthetaseProteinunknownNot AvailableBacillus subtilis (strain 168)P08164 details
Dihydrofolate reductaseProteinunknownNot AvailableHumanP00374 details
Related Articles
AbsorptionInjections lead to peak serum concentrations in 30-60 minutes. Topical gentamicin is readily absorbed from large burned, denuded, or granulating areas but not through intact skin. Absorption of gentamicin is faster and greater with the cream compared to the ointment. Gentamicin is absorbed in small quantities following topical application to the eye. Gentamicin is also absorbed in small amounts following topical application to the ear (especially if the eardrum is perforated or if tissue damage is present). Gentamicin is very poorly absorbed orally.
Volume of distributionNot Available
Protein bindingLow (between 0 and 30%)
MetabolismNot Available
Route of eliminationNot Available
Half life3-3½ hours in infants one week to six months of age; this increases to 5½ hours in full-term and large premature infants less than one week old.
ClearanceNot Available
ToxicityMild and reversible nephrotoxicity may be observed in 5 - 25% of patients. Gentamicin accumulates in proximal renal tubular cells and causes cell damage. Tubular cell regeneration occurs despite continued drug exposure. Toxicity usually occurs several days following initiation of therapy. May cause irreversible ototoxicity. Otoxocity appears to be correlated to cumulative lifetime exposure. Drug accumulation in the endolymph and perilymph of the inner ear causes irreversible damage to hair cells of the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing is lost first with progression leading to loss of low frequency hearing. Further toxicity may lead to retrograde degeneration of the 8th cranial (vestibulocochlear) nerve. Vestibular toxicity may cause vertigo, nausea, vomiting, dizziness and loss of balance. Mouse, intravenous LD50: 52 mg/kg; rat, intravenous LD50: 96 mg/kg.
Affected organisms
  • Enteric bacteria and other eubacteria
  • Pseudomonas aeruginosa
  • Yersinia pestis
  • Francisella tularensis
  • Serratia marcescens
  • Proteus vulgaris
Pathways
PathwayCategorySMPDB ID
Gentamicin Action PathwayDrug actionSMP00254
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
AcetovanilloneAcetovanillone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Gentamicin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
Agalsidase betaThe therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Gentamicin.Approved, Investigational
Alendronic acidGentamicin may increase the hypocalcemic activities of Alendronic acid.Approved
AmdinocillinThe serum concentration of Gentamicin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Gentamicin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Gentamicin.Approved, Investigational
AmpicillinThe serum concentration of Gentamicin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AnisodamineAnisodamine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
AnvirzelThe serum concentration of Anvirzel can be decreased when it is combined with Gentamicin.Investigational
ApremilastApremilast may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
Atracurium besylateGentamicin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Gentamicin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Gentamicin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Gentamicin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Gentamicin.Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Gentamicin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Gentamicin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicillin PotassiumThe serum concentration of Gentamicin can be decreased when it is combined with Benzylpenicillin Potassium.Approved
Benzylpenicilloyl PolylysineThe serum concentration of Gentamicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
Betulinic AcidBetulinic Acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
Botulinum Toxin Type AGentamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BGentamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Gentamicin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Gentamicin.Approved
CarbenicillinThe serum concentration of Gentamicin can be decreased when it is combined with Carbenicillin.Approved
CarboplatinGentamicin may increase the ototoxic activities of Carboplatin.Approved
CarindacillinThe serum concentration of Gentamicin can be decreased when it is combined with Carindacillin.Approved
CarprofenCarprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
Cisatracurium besylateGentamicin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Gentamicin.Approved
ClodronateGentamicin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Gentamicin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateGentamicin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Gentamicin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineGentamicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
DecamethoniumGentamicin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Gentamicin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Gentamicin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalDiflunisal may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Gentamicin.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Gentamicin.Approved
Domoic AcidGentamicin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideGentamicin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
E6201E6201 may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
EbselenEbselen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
EpirizoleEpirizole may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Gentamicin.Approved
EtanerceptEtanercept may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
Etidronic acidGentamicin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
FenbufenFenbufen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
FloctafenineFloctafenine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Gentamicin can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Gentamicin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Gentamicin.Approved, Vet Approved
Gallamine TriethiodideGentamicin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
HigenamineHigenamine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
HMPL-004HMPL-004 may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
IbandronateGentamicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
IndomethacinIndomethacin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
LeflunomideLeflunomide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
LornoxicamLornoxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Gentamicin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
MecamylamineGentamicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Gentamicin which could result in a higher serum level.Withdrawn
MeticillinThe serum concentration of Gentamicin can be decreased when it is combined with Meticillin.Approved
MetocurineGentamicin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideGentamicin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Gentamicin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumGentamicin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
NafcillinThe serum concentration of Gentamicin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
NeosaxitoxinGentamicin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
OlopatadineOlopatadine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Gentamicin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Gentamicin.Approved
OxacillinThe serum concentration of Gentamicin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Withdrawn
PamidronateGentamicin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumGentamicin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
PhenoxymethylpenicillinThe serum concentration of Gentamicin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gentamicin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
PipecuroniumGentamicin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Gentamicin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Gentamicin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
PivampicillinThe serum concentration of Gentamicin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Gentamicin can be decreased when it is combined with Pivmecillinam.Approved
Procaine benzylpenicillinThe serum concentration of Gentamicin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
PropacetamolPropacetamol may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
PTC299PTC299 may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
PyrantelGentamicin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumGentamicin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Gentamicin which could result in a higher serum level.Experimental, Investigational
RisedronateGentamicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumGentamicin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
SeratrodastSeratrodast may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
SRT501SRT501 may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
SuccinylcholineGentamicin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Gentamicin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Gentamicin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Withdrawn
TazobactamThe serum concentration of Gentamicin can be decreased when it is combined with Tazobactam.Approved
Technetium tc 99m etidronateGentamicin may increase the hypocalcemic activities of Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateGentamicin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
TenofovirThe serum concentration of Gentamicin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Gentamicin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
TiludronateGentamicin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Gentamicin.Approved
TranilastTranilast may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
TubocurarineGentamicin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Gentamicin.Approved
VecuroniumGentamicin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidGentamicin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

George H. Scherr, “Preparation of gentamicin sensitized particles for agglutination tests.” U.S. Patent US4100268, issued August, 1975.

US4100268
General ReferencesNot Available
External Links
ATC CodesS02AA14S01AA11D06AX07S03AA06J01GB03
AHFS Codes
  • 08:12.02
  • 52:04.04
  • 84:04.04
PDB Entries
FDA labelNot Available
MSDSDownload (59.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.944
Blood Brain Barrier-0.9826
Caco-2 permeable-0.6987
P-glycoprotein substrateSubstrate0.6882
P-glycoprotein inhibitor INon-inhibitor0.6808
P-glycoprotein inhibitor IINon-inhibitor0.9586
Renal organic cation transporterNon-inhibitor0.8738
CYP450 2C9 substrateNon-substrate0.8001
CYP450 2D6 substrateNon-substrate0.8314
CYP450 3A4 substrateSubstrate0.5917
CYP450 1A2 substrateNon-inhibitor0.9034
CYP450 2C9 inhibitorNon-inhibitor0.891
CYP450 2D6 inhibitorNon-inhibitor0.9331
CYP450 2C19 inhibitorNon-inhibitor0.9043
CYP450 3A4 inhibitorNon-inhibitor0.9517
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9294
Ames testNon AMES toxic0.7338
CarcinogenicityNon-carcinogens0.9696
BiodegradationNot ready biodegradable0.9588
Rat acute toxicity2.0383 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9954
hERG inhibition (predictor II)Non-inhibitor0.8784
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Schering corp sub schering plough corp
  • Pharmafair inc
  • Alpharma us pharmaceuticals division
  • Bausch and lomb pharmaceuticals inc
  • E fougera div altana inc
  • Perrigo new york inc
  • Pharmaderm div altana inc
  • Taro pharmaceuticals usa inc
  • King pharmaceuticals inc
  • Bristol laboratories inc div bristol myers co
  • International medication systems ltd
  • Abbott laboratories pharmaceutical products div
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Kalapharm inc
  • Pharmaceutical specialist assoc
  • Solopak laboratories inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • B braun medical inc
  • Baxter healthcare corp
  • Pharmacia and upjohn co
  • Novartis pharmaceuticals corp
  • Akorn inc
  • Altana inc
  • Allergan
  • Alcon universal ltd
  • Falcon pharmaceuticals ltd
  • Paco research corp
Packagers
Dosage forms
FormRouteStrength
LiquidIntramuscular; Intravenous40 mg
LiquidIntramuscular; Intravenous10 mg
OintmentOphthalmic.3 %
LiquidOphthalmic.3 %
LiquidAuricular (otic); Ophthalmic
CreamTopical.1 %
SolutionOphthalmic3 mg/mL
Solution / dropsOphthalmic5 mg
Solution / dropsAuricular (otic)5 mg
Solution / dropsOphthalmic3 mg
Injection, solutionIntramuscular; Intravenous10 mg/mL
SolutionOphthalmic.3 %
SolutionIntramuscular; Intravenous10 mg
SolutionIntramuscular; Intravenous40 mg
CreamTopical1 mg/g
Injection, solutionIntramuscular; Intravenous40 mg/mL
Injection, solution, concentrateIntramuscular; Intravenous40 mg/mL
Injection, solution, concentrateIntravenous10 mg/mL
OintmentOphthalmic3 mg/g
OintmentTopical1 mg/g
Solution / dropsOphthalmic3 mg/mL
SolutionIntravenous
Injection, solutionIntravenous.8 mg/mL
Injection, solutionIntravenous.9 mg/mL
Injection, solutionIntravenous1 mg/mL
Injection, solutionIntravenous1.2 mg/mL
Injection, solutionIntravenous1.4 mg/mL
Injection, solutionIntravenous1.6 mg/mL
Injection, solutionIntravenous100 mg/100mL
Injection, solutionIntravenous100 mg/50mL
Injection, solutionIntravenous60 mg/50mL
Injection, solutionIntravenous80 mg/100mL
Injection, solutionIntravenous80 mg/50mL
SolutionIntravenous1 mg
SolutionIntravenous1.2 mg
SolutionIntravenous1.6 mg
Solution / dropsOphthalmic; Topical0.3 %
LiquidOphthalmic; Topical3 mg
OintmentOphthalmic; Topical3 mg
OintmentOphthalmic5 mg
SolutionOphthalmic5 mg
CreamTopical1 mg
OintmentTopical1 mg
OintmentOphthalmic0.3 %
Solution / dropsAuricular (otic)3 mg
OintmentOphthalmic
Suspension / dropsOphthalmic
CreamTopical0.1 %
OintmentTopical.1 %
LiquidOphthalmic3 mg
OintmentOphthalmic3 mg
SolutionAuricular (otic)3 mg
SolutionAuricular (otic); Ophthalmic
ImplantParenteral4.5 mg
CreamTopical
OintmentTopical
Prices
Unit descriptionCostUnit
Gentak 0.3% Ointment 3.5 gm Tube19.99USD tube
Gentamicin Sulfate 0.1% Cream 15 gm Tube12.99USD tube
Gentamicin Sulfate 0.1% Ointment 15 gm Tube11.99USD tube
Gentamicin Sulfate 0.3% Solution 5ml Bottle11.99USD bottle
Gentamicin sulfate powder5.05USD g
Gentamicin Sulfate 10 mg/ml Solution 2ml Vial5.0USD vial
Gentamicin 40 mg/ml2.82USD ml
Gentamicin ped 10 mg/ml vial2.4USD ml
Gentak 3 mg/ml eye drops1.91USD ml
Gentamicin 3 mg/ml eye drops1.89USD ml
Gentamicin 10 mg/ml vial1.29USD ml
Garamycin 0.3 % Ointment1.2USD g
Sandoz Gentamicin Sulfate 0.3 % Ointment1.2USD g
Garamycin 0.3 % Solution0.75USD ml
Sandoz Gentamicin Sulfate 0.3 % Solution0.75USD ml
Gentamicin 40 mg/ml vial0.45USD ml
Ratio-Gentamicin Sulfate 0.1 % Cream0.43USD g
Ratio-Gentamicin Sulfate 0.1 % Ointment0.37USD g
Gentamicin 0.1% cream0.16USD g
Iso gentamicin 120 mg/100 ml0.09USD ml
Gentamicin 90 mg/ns 100 ml pb0.05USD ml
Isoton gentamicin 40 mg/100 ml0.05USD ml
Gentamicin 60 mg/ns 100 ml pb0.04USD ml
Gentamicin 100 mg/ns 100 ml0.03USD ml
Gentamicin 80 mg/ns 100 ml pb0.03USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point105 °CPhysProp
water solubility100 mg/mLNot Available
logP-3.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility12.6 mg/mLALOGPS
logP-1.6ALOGPS
logP-3.1ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)12.55ChemAxon
pKa (Strongest Basic)10.18ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area199.73 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity118.02 m3·mol-1ChemAxon
Polarizability51.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0i29-1319700000-e55d2931137c5abc8493View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-03di-0904000000-de986ac47725d8f3a72aView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0592-9602000000-c7fd77457525743faebaView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-014i-2911100000-93e47b752e7992b12263View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-014i-2958400000-7303bf3ebe16dd1c1d60View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0udi-2692000000-a8234ed8e0131019f62bView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassAminosaccharides
Direct ParentAminoglycosides
Alternative Parents
Substituents
  • Aminoglycoside core
  • 2-deoxystreptamine aminoglycoside
  • Glucosamine
  • Amino sugar
  • O-glycosyl compound
  • Glycosyl compound
  • Cyclohexylamine
  • Cyclohexanol
  • Oxane
  • Monosaccharide
  • Tertiary alcohol
  • Cyclic alcohol
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Oxacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Acetal
  • Hydrocarbon derivative
  • Primary amine
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
adduct
General Function:
Trna binding
Specific Function:
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Located at the interface of the 30S and 50S subunits, it traverses the body of the 30S subunit contacting proteins on the other side and probably holding the rRNA structure together. The combined cluste...
Gene Name:
rpsL
Uniprot ID:
P0A7S3
Molecular Weight:
13736.995 Da
References
  1. Gill AE, Amyes SG: The contribution of a novel ribosomal S12 mutation to aminoglycoside resistance of Escherichia coli mutants. J Chemother. 2004 Aug;16(4):347-9. [PubMed:15332709 ]
  2. Tamehiro N, Hosaka T, Xu J, Hu H, Otake N, Ochi K: Innovative approach for improvement of an antibiotic-overproducing industrial strain of Streptomyces albus. Appl Environ Microbiol. 2003 Nov;69(11):6412-7. [PubMed:14602594 ]
  3. Hu H, Ochi K: Novel approach for improving the productivity of antibiotic-producing strains by inducing combined resistant mutations. Appl Environ Microbiol. 2001 Apr;67(4):1885-92. [PubMed:11282646 ]
  4. Schroeder R, Waldsich C, Wank H: Modulation of RNA function by aminoglycoside antibiotics. EMBO J. 2000 Jan 4;19(1):1-9. [PubMed:10619838 ]
2. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
yes
Actions
adduct
References
  1. Doi Y, de Oliveira Garcia D, Adams J, Paterson DL: Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob Agents Chemother. 2007 Mar;51(3):852-6. Epub 2006 Dec 11. [PubMed:17158944 ]
  2. Bogaerts P, Galimand M, Bauraing C, Deplano A, Vanhoof R, De Mendonca R, Rodriguez-Villalobos H, Struelens M, Glupczynski Y: Emergence of ArmA and RmtB aminoglycoside resistance 16S rRNA methylases in Belgium. J Antimicrob Chemother. 2007 Mar;59(3):459-64. Epub 2007 Jan 15. [PubMed:17224412 ]
  3. Aslangul E, Massias L, Meulemans A, Chau F, Andremont A, Courvalin P, Fantin B, Ruimy R: Acquired gentamicin resistance by permeability impairment in Enterococcus faecalis. Antimicrob Agents Chemother. 2006 Nov;50(11):3615-21. [PubMed:17065620 ]
  4. Schroeder R, Waldsich C, Wank H: Modulation of RNA function by aminoglycoside antibiotics. EMBO J. 2000 Jan 4;19(1):1-9. [PubMed:10619838 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
other/unknown
General Function:
Calcium ion binding
Specific Function:
Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.
Gene Name:
LRP2
Uniprot ID:
P98164
Molecular Weight:
521952.77 Da
References
  1. Watanabe A, Nagai J, Adachi Y, Katsube T, Kitahara Y, Murakami T, Takano M: Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. J Control Release. 2004 Mar 24;95(3):423-33. [PubMed:15023454 ]
  2. Takamoto K, Kawada M, Ikeda D, Yoshida M: Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C. Biochim Biophys Acta. 2005 Apr 15;1722(3):247-53. [PubMed:15777622 ]
  3. Nagai J, Saito M, Adachi Y, Yumoto R, Takano M: Inhibition of gentamicin binding to rat renal brush-border membrane by megalin ligands and basic peptides. J Control Release. 2006 May 1;112(1):43-50. Epub 2006 Feb 20. [PubMed:16488503 ]
Kind
Protein
Organism
Bacillus subtilis (strain 168)
Pharmacological action
unknown
General Function:
Nad+ synthase activity
Specific Function:
Catalyzes a key step in NAD biosynthesis, transforming deamido-NAD into NAD by a two-step reaction.
Gene Name:
nadE
Uniprot ID:
P08164
Molecular Weight:
30394.995 Da
References
  1. Velu SE, Cristofoli WA, Garcia GJ, Brouillette CG, Pierson MC, Luan CH, DeLucas LJ, Brouillette WJ: Tethered dimers as NAD synthetase inhibitors with antibacterial activity. J Med Chem. 2003 Jul 17;46(15):3371-81. [PubMed:12852767 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Nadph binding
Specific Function:
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
Gene Name:
DHFR
Uniprot ID:
P00374
Molecular Weight:
21452.61 Da
References
  1. Al-Omary FA, Abou-Zeid LA, Nagi MN, Habib el-SE, Abdel-Aziz AA, El-Azab AS, Abdel-Hamide SG, Al-Omar MA, Al-Obaid AM, El-Subbagh HI: Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorg Med Chem. 2010 Apr 15;18(8):2849-63. doi: 10.1016/j.bmc.2010.03.019. Epub 2010 Mar 12. [PubMed:20350811 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [PubMed:10411577 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 17:02